CSL112 data due 16th Nov, next CSL pipeline blockbuster

Been doing some research on this CSL112 and the data will be presented on the 15th Nov in New Orleans at the American Heart Association conference.

It is a 1200 patient study of patients who just had a heart attack and they get an infusion of a by-product of plasma fractionation based on HDL or good cholesterol.

Could be worth $29/share.

This is a large safety read-out but I think CSL will partner this to do a confirmation study or go alone. Massive product with peak sales estimated at US$1.5bn, 47% net profit. There is 550k new heart attack patients in the US alone at the product would sell for around US$15k.

If there was any safety issue the independent safety monitoring board would of stopped the study so it looks to be positive and the market hasn't factored anything for this yet. Well until next Thursday morning Australia time.